GlassScriptPhysician profile
Rajendra Prasad
NPI 1619937885
$5,881.43
in general payments reported to CMS, 2019-2025
36 companies · $984 in 2025
The $984 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $384 · 2021: $721 · 2022: $759 · 2023: $1,134 · 2024: $791 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $854.58 | 2019-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $464.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $417.89 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.21 | 2020-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $378.74 | 2019-2024 | Lifevest |
| Pfizer INC. | $375.34 | 2021-2025 | |
| Amarin Pharma, INC. | $266.50 | 2019-2022 | |
| Terumo Medical Corporation | $264.64 | 2025 | Navicross, Glidewire, Azur Cx Detachable |
| Heartflow, INC. | $234.38 | 2023-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $231.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.88 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $175.90 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $167.21 | 2019-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $166.24 | 2022-2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $163.31 | 2020-2024 | Wegovy, Rybelsus, Ozempic |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.